58P Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

Value in Health ◽

10.1016/j.jval.2019.09.048 ◽

2019 ◽

Vol 22 ◽

pp. S405-S406

Author(s):

X. Guan ◽

H. Li ◽

Q. Chen ◽

C. Hao ◽

J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

High Risk ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Her2 Positive ◽

Risk Of Recurrence ◽

PCN7 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT THERAPY WITH TRASTUZUMAB FOR HER2-POSITIVE EARLY BREAST CANCER IN POLISH SETTING

Value in Health ◽

10.1016/s1098-3015(10)68918-8 ◽

2007 ◽

Vol 10 (3) ◽

pp. A125 ◽

Cited By ~ 1

Author(s):

E Orlewska ◽

T Pienkowski ◽

K Drosik ◽

M Gyldmark ◽

R Aultman ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Therapy ◽

Early Breast Cancer ◽

Her2 Positive ◽

Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States

American Journal of Clinical Oncology ◽

10.1097/coc.0000000000000816 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Jesse Sussell ◽

Gurleen Singh Jhuti ◽

Vincent Antao ◽

Oscar Herrera-Restrepo ◽

Elizabeth Wehler ◽

...

Keyword(s):

Breast Cancer ◽

United States ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

The United States ◽

Trastuzumab Emtansine ◽

PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING

Value in Health ◽

10.1016/s1098-3015(10)66557-6 ◽

2008 ◽

Vol 11 (6) ◽

pp. A465-A466

Author(s):

H AlOmar ◽

AS Zazaa ◽

M AlFayyadh ◽

JA Ray

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Saudi Arabian ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Cost-Effectiveness Analysis of Ado-Trastuzumab Emtansine Compared to Lapatinib-Capecitabine Combination In Her2-Positive Metastatic Breast Cancer

Value in Health ◽

10.1016/j.jval.2015.03.1186 ◽

2015 ◽

Vol 18 (3) ◽

pp. A205 ◽

Cited By ~ 1

Author(s):

D. Gor ◽

W. Lee ◽

K. Kim ◽

A. Mohan ◽

K. Peng ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cost Effectiveness ◽

Metastatic Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results

Annals of Oncology ◽

10.1093/annonc/mdy424.001 ◽

2018 ◽

Vol 29 ◽

pp. viii703 ◽

Cited By ~ 2

Author(s):

C. Hulme ◽

P. Hall ◽

B. Shinkins ◽

F. Chehadah ◽

C. McCabe ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

PCN31 Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment for Patients with HER2-Positive EARLY Breast Cancer: Update Results after National Drug Reimbursement LIST Adjustment in China

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.081 ◽

2020 ◽

Vol 22 ◽

pp. S10

Author(s):

X. Guan ◽

H.C. Li ◽

Q.J. Chen ◽

C.F. Hao ◽

J.J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Her2 Positive ◽

Drug Reimbursement ◽

Effectiveness Analysis ◽

National Drug ◽

Reimbursement List

PCN103 Cost-Effectiveness Analysis of Trastuzumab Emtansine for Adjuvant Treatment of Adult Patients with HER2+ EARLY Breast Cancer in Turkey

Value in Health ◽

10.1016/j.jval.2020.08.240 ◽

2020 ◽

Vol 23 ◽

pp. S441

Author(s):

B. Akyol Ersoy ◽

E. Erdogan-Ciftci ◽

L. Yanik ◽

B. Guler ◽

G. Ozcan

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Adult Patients ◽

Trastuzumab Emtansine ◽

Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China

Clinical Drug Investigation ◽

10.1007/s40261-021-01035-4 ◽

2021 ◽

Author(s):

Huahua Zhang ◽

Yandong Zhang ◽

Chaonan Huang ◽

Jiangfeng Wang

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Trastuzumab Emtansine ◽

Second Line ◽

Her2 Positive ◽

Second Line Therapy ◽

Effectiveness Analysis ◽

Line Therapy ◽

Positive Breast Cancer

Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1909478 ◽

2021 ◽

pp. 1-10

Author(s):

Carlos Henrique Botelho ◽

Maria Del Pilar Estevez-Diz ◽

Alessandro Gonçalves Campolina

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽